Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Dificid (fidaxomicin by Year
Dificid (fidaxomicin — C. difficile infection) — Worldwide reported growth YoY (%) (%)
Merck Dificid (fidaxomicin: -27.0% in FY2025, down 40.0 pts from a year earlier.
Latest, FY2025
-27.0%
Period ended Dec 31, 2025
Change on a year earlier
-40.0 pts
13.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Dificid | 247 | 340 | -27 | 202 | 303 | -33 | 45 | 37 | 20”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Dificid (fidaxomicin — C. difficile infection) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -27.0% | -40.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 13.0% | -2.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 15.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
Cite this data
StockData. (2026). Merck Dificid (fidaxomicin (%), annual FY2023–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-dificid-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.